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Abstract 
Background and Aim: Prostate cancer (PC) is one of the most prevalent cancers with high mortality and morbidity in 
men, which can be treated in different ways before the progression and metastasis to distant organs. Destruction of 
extracellular matrix by matrix metalloproteinase (MMP), particularly by the 2 and 9 subtypes, has an important role in 
the metastasis of PC. We aimed to assess the activity of MMP 2 and 9 and some related metalloproteinases in PC and 
with benign prostate hyperplasia (BPH) patients in comparison to healthy individuals. 
Methods: In this case-control study, 72 individuals referred to Imam Khomeini hospital (Tehran, Iran), have been 
divided into 3 groups, including PC, BPH, and healthy control. Age and body mass index (BMI) for all groups have 
been matched. Venous blood samples were used to assess the enzyme activity by the zymography technique.  
Results: The activity of MMP-2 and 9 was significantly higher in PC than BPH and control groups. But there was no 
difference in the activity of enzymes in patients with PC according to the Gleason score.  
Conclusion: The results suggested that MMPs activity can be considered a diagnostic marker for PC. However, further 
studies are required to establish this concept. 
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Prostate cancer (PC) is one of the most prevalent 
malignancies in men worldwide. In 2018, 164690 
new cases of the disease have been reported in the 
United States. Among them, approximately 29430 
patients passed away. PC contains 19.23% of all 
cancer morbidity and 9% of all cancer-related death 
in the men population worldwide (1). 
This cancer can be treated by current strategies if it 
is limited to just prostate tissue. But, the treatment 
almost is not completely effective when it 
metastases to other tissues. The metastasis is a 
complex cascade process leading to tumor cell 
migration, attachment, and invasion. Cellular 
invasion contains the tumor cell translocation across 
the extracellular matrix barrier as a known 
important biological event needed for tumor 
metastasis (2). 
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The MMPs are a family of proteolytic enzymes that 
degrade extracellular matrix components such as 
collagen, fibronectin, and laminin (3). The most 
important component of the basal membrane is 
collagen IV, which is degraded by MMP-9. In this 
regard, the evaluation of MMP-9 proteolytic 
activity is essential for an understanding of basal 
membrane change and repair mechanisms and 
abnormal collagen destruction in pathologic 
conditions such as atherosclerosis, cancer, and 
rheumatoid arthritis (4-7).  
Among all types of MMPs, MMP-2, 9 can degrade 
abnormal collagen and the types of IV, V, VII, IX. 
Recently their role in apoptosis, differentiation, 
angiogenesis, immune responses, and tumor cell 
growth has been revealed (8). The MMP-9 
expression was associated with a higher rate of 
metastasis; it was confirmed that the enzyme 
inhibitors reduced the metastasis rate of PC (9). The 
MMP-9 expression was higher in the serum and 
tissue of PC compared to BPH (10, 11). The 
increasing MMP-2 expression is associated with a 
decreased survival rate in patients with PC (12, 13). 
MMP-2 also was known as an activator of MMP-9. 
(14). Therefore, it aimed to assess the activity of 
MMP-2 and 9 in PC and BPH patients in 
comparison to healthy men.  
Methods 
Among the patients who were referred to the 
urology center in the Imam Khomeini hospital in 
Tehran City during 2018-2019, Forty-eight patients 
were selected and after the biopsy and pathological 
tests were divided into two groups: PC group 
(n=24) and BPH (n= 24). The Third group included 
24 healthy people. Exclusion criteria in the PC 
group include the patients who were diagnosed with 
more than one year of diseases and who received 
anti-cancer drugs, chemotherapy, hormone therapy, 
and radiotherapy. Inclusion criteria in the BPH 
group include the BPH detection and PC ruling out 
according to histological survey following open 
prostatectomy.  
Exclusion criteria in the BPH group include the 
patients with a history of cancer, received 
finasteride more than one month and anti-cancer 
drugs, and whose prostate histological evaluation 
showed a section suspected to prostate 
intraepithelial neoplasia (PIN).  
All the individuals who entered the study signed the 
testimonial consciously and with desire.  
Blood sampling 
From all individuals, about 2.5 mL of blood 
samples were collected into tubes without any 
coagulant agents from the forearm, and serum was 
extracted and used for zymography tests. 
Zymography 
Serum samples were electrophoresed on 
polyacrylamide gel 10% with sodium dodecyl 
sulfate (SDS-PAGE) and gelatin 1% (gelatinase 
substrate). After electrophoresis, the gel was 
incubated in 2% Triton X-100 solution in 
Phosphate-buffered saline (PBS) for one hour at 
room temperature and then in Tris-HCL (pH 7.4, 
containing 10 mmol calcium-chloride) for 16 hours 
at 37°C. Following washing, the gel was stained by 
0.05% coomassie brilliant blue G-250. Then, the 
destaining was done with a solution of water: 
methanol: acetic acid with a ratio of 60%, 30%, and 
10%, respectively. The destained bands produced 
by MMP-9, MMP-2, MMP-9/NGAL, and dimmer 
MMP-9 activity appeared in a purple background. 
Protein weight markers (Color Burst, Sigma 
Aldrich; USA) were used to confirm the identity of 
the gelatinase band. After the complete destaining, 
the gels have been filled between two transparent 
films and scanned by a Canon scanner (LiDE110, 
Japan). 
Quantification of bands produced by gelatinase 
activation 
Colorless bands of zymography gels produced by 
the activity of MMP-9, MMP-2, MMP-9/NGAL, 
and dimmer MMP-9 were quantified by 
measurement of the bands' area with ImageJ 
software. 
Statistical analysis 
To compare the mean activity of MMP-9, MMP-2, 
MMP-9/NGAL, and Dimmer MMP-9 enzymes in 
patients groups with the healthy group, the SPSS-20 
software was used for statistical analysis and T-test, 
ANOVA and Tukey tests were used and the results 
were reported in Mean ±standard deviation (SD). 
Bivariate correlation test and Spearman's rho 
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statistical method were also used to investigate the 
association between marker activity and cancer 
stage. All results reported in 95% confidence 
interval (CI) and p-value <0.05 were considered 
significant. 
Results 
The demographic results were compared between 
three PC, BPH, and cancer (Table 1). There were no 
statistical differences between the three groups in 
age and BMI, so we considered that the groups are 
matched. The groups were also examined for 
smoking and family history. There were no 
statistical differences between groups according to 
familial history and smoking. 
 
Table 1. Comparison of the demographic result between the three groups 
Characteristics N Mean± SD P-value 
Age (year) 
PC 24 64.00± 6.11 
0.597 BPH 24 66.63± 6.40 
control 24 65.85±10.69 
BMI (Kg/m2) 
PC 24 23.21± 3.21 
0.297 BPH 24 22.16± 3.20 
control 24 23.61± 3.08 
Familial history 
  N percent  
PC 
Yes  2 08.34 
0.357 
No 22 91.66 
BPH 
Yes  1 04.17 
No 23 95.83 
control 
Yes  0 0 
No 24 100 
Smoking 
PC 
Yes  7 29.17 
0.163 
No 17 70.83 
BPH 
Yes  4 16.67 
No 20 83.33 
control 
Yes  10 41.67 
No 14 58.33 
PC: Prostate cancer; MMP: matrix metalloproteinase; BPH: benign prostate hyperplasia 
 
It can be seen from the data in Table 2 that there 
is a significant difference in the quantitative 
activity of MMPs except for MMP-9/NGAL 
between the three groups. Tukey test was used to 
determine the difference of quantitative activity 
of MMPs between each group. The data shown 
in Table 3 demonstrated that the Dimmer MMP-
9 between cancer and control groups, the MMP-9 
and MMP-2 between the cancer group with the 
control and BPH groups differed significantly. 
Table 2. Comparison of the quantified activity level of MMPs between three groups 
Variables Mean±SD p-value 
Dimmer MMP-9 (IU) 
PC 163.35± 40.85 








0.001 BPH 144.90±90.77 
control 193.96±50.25 
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MMP-2 (IU) 
PC 113.18±65.38 
0.019 BPH 70.59±44.23 
control 71.24±26.33 
PC: Prostate cancer; MMP: matrix metalloproteinase; BPH: benign prostate hyperplasia 
Table 3. Multiple Comparison of the quantified activity level of MMPs between each group 
Enzyme Groups p-value 
Dimmer MMP-9 (IU) PC control 0.006 
MMP-9 (IU) PC 
BPH 0.000 
control 0.041 
MMP-2 (IU) PC 
BPH 0.026 
control 0.041 
PC: Prostate cancer; MMP: matrix metalloproteinase; BPH: benign prostate hyperplasia 
 
The prognosis of men with prostate cancer 
evaluated by the Gleason grading system (Table 
4). The prostate tissues that they have prepared 
by the biopsy, are evaluated by the pathologists 
and as cancer progresses, they give it a score of 2 
to 9. The higher numbers indicate greater risks 
and higher mortality. The results demonstrate 
that when patients with PC are divided into two 
groups according to the Gleason score of ˃7 and 
≤7, no differences are seen in the activity of the 
enzymes. The correlation analysis between 
different factors demonstrated that MMP-9 
positively correlated with MMP-2 (R: 0.708; P ˂ 
0.001). Other factors showed no significant 
correlations. 
 
Table 4. Comparison of the quantified activity level of MMPs in patients with PC based on the Gleason score 
Variables GS divided Mean Std. Deviation p-value 
Age (year) 
˃7 64.50 7.06 
0.810 
≤7 63.70 5.85 
BMI (kg/m2) 
˃7 22.24 1.75 
0.285 
≤7 23.79 3.80 
Dimmer MMP-9 (IU) 
˃7 161.41 30.67 
0.899 
≤7 164.57 48.16 
MMP-9/NGAL (IU) 
˃7 22.09 17.87 0.806 
 ≤7 19.64 20.50 
MMP-9 (IU) 
˃7 293.31 180.96 
0.977 
≤7 290.99 118.13 
MMP-2 (IU) ˃7 143.97 63.78 0.282 
 
Discussion 
The important processes in cancer development are 
angiogenesis, metastasis, and distribution of tumor 
cells far from the original location. The process of 
angiogenesis includes the growth and branching of 
blood vessels in tumor tissue (15, 16). Several 
studies illustrated that MMPs such as MMP-2 and 
MMP-9 have a key role in angiogenesis (17-21). 
Trudel D et al. demonstrated MMP-9 is over-
expressed in high-grade prostate tumor cells and 
also in benign stromal and epithelial cells in the 
early stages (22). These findings were in line with 
our results. In the present study, MMP-9 activity 
was 291.98 in patients with PC, while in the BPH 
and control groups, it was 144.9 and 193.96, 
respectively. Moreover, these results showed that 
MMP-9 activity significantly increased in prostate 
cancer. These results were not consistent with 
Rodrígue G et al. results that they didn’t observe 
any association between the plasma expression of 
MMP-9 and prostate syndromes, so it can’t be 
considered as a marker for PC diagnosis (23). 
According to previous studies, it can be concluded 
that MMP-9 isn’t a proper diagnostic marker but 
can be considered as a target molecule for inhibiting 
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tumor progression. Based on current results, both 
MMP-2 and MMP-9 enzymes can be used as 
diagnostic markers because their expression is not 
significantly different in healthy men and benign 
prostatic hyperplasia, but in the group of prostate 
cancer with both healthy and BPH is significantly 
different. 
Morgia G et al. investigated the MMP-13 as a 
diagnostic marker and MMP-2, 9 as prognostic 
markers in PC. They concluded that the plasma 
level and activity of MMPs concomitant with PSA 
determination can play a key role in the diagnosis, 
treatment, and screening of prostate cancer (11). 
Wilson et al. reported that produced protease-
activated receptors 1 and 2 (PAR-1 and PAR-2) can 
increase the activity of MMP-2, 9 in PC cells that 
confirm their role in PC metastasis (24). Our result 
consistent with Wilson’s research demonstrated 
MMP-2 activity in patients with PC is remarkably 
higher than the BPH and the control group. Hamdy 
F.C et al. and Festuccia C et al. showed the 
elevation of MMP-9 levels in patients with PC 
compared to BPH (25, 26). But several studies 
reported opposite results. Lokeshwar et al. (27) 
revealed that BPH caused a higher level of MMP-9 
in comparison to patients with PC, while the level 
of MMP-2 in PC samples was more than BPH (28-
31). Similar studies proved an increased level of 
MMP-2 in PC compare to BPH, however, 
Upadhyay et al. (32) didn’t observe any significant 
difference in MMP-2 expression among patients 
with PC and healthy control. No definitive 
specificity of these enzymes for cancer was found 
in this study, but it is confirmed that they are 
significantly higher in cancer patients. On the other 
hand, in people who have recently been diagnosed 
with prostate cancer, they can be used as specific 
therapeutic targets in the cancer site. 
Conclusion 
The results suggested that MMPs activity can be 
considered a diagnostic marker for PC. However, 
further studies are required to establish this concept. 
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